Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs.
The effects of long-term treatment with imipramine or mirtazapine, two antidepressant drugs with different mechanisms of action, on the response of cortical dopaminergic neurons to foot-shock stress or to the anxiogenic drug FG7142 were evaluated in freely moving rats. As expected, foot shock induced a marked increase (+ 90%) in the extracellular concentration of dopamine in the prefrontal cortex of control rats. Chronic treatment with imipramine or mirtazapine inhibited or prevented, respectively, the effect of foot-shock stress on cortical dopamine output. Whereas acute administration of the anxiogenic drug FG7142 induced a significant increase (+ 60%) in cortical dopamine output in control rats, chronic treatment with imipramine or mirtazapine completely inhibited this effect. In contrast, the administration of a single dose of either antidepressant 40 min before foot shock, had no effect on the response of the cortical dopaminergic innervation to stress. These results show that long-term treatment with imipramine or mirtazapine inhibits the neurochemical changes elicited by stress or an anxiogenic drug with an efficacy similar to that of acute treatment with benzodiazepines. Given that episodes of anxiety or depression are often preceded by stressful events, modulation by antidepressants of the dopaminergic response to stress might be related to the anxiolytic and antidepressant effects of these drugs.
Dazzi
L
L
Department of Experimental Biology 'B. Loddo', Chair of Pharmacology, University of Cagliari, Cagliari, Italy. dazzi@vaxca1.unica.it
Spiga
F
F
Pira
L
L
Ladu
S
S
Vacca
G
G
Rivano
A
A
Jentsch
J D
JD
Biggio
G
G
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001007:Anxiety / Q000139:chemically induced / Q000378:metabolism*; D002243:Carbolines / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004597:Electroshock; D018756:GABA Antagonists; D007099:Imipramine / Q000008:administration & dosage; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017551:Microdialysis; D000078785:Mirtazapine; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D000928:Antidepressive Agents; D002243:Carbolines; D018756:GABA Antagonists; D008803:Mianserin; C035874:FG 7142; D000078785:Mirtazapine; D007099:Imipramine; D004298:Dopamine